Manish R. Patel, Alberto J. Montero, Alexander I. Spira, Babar Bashir, Debra L. Richardson, Ricardo L. Costa, Sanjay Thamake, Denise Trone, Patricia LoRusso. "A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) and cyclin E1 (CCNE1)–amplified solid tumors: Updated safety and efficacy results.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1094